Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095498
Status:
COMPLETED
Last Update Posted:
2021-10-25
First Post:
2004-11-05
Brief Title:
Efficacy Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Multi-dose Phase 2 Study to Determine the Efficacy Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the efficacy safety and tolerability of denosumab AMG 162 in the treatment of Rheumatoid Arthritis RA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None